# US 2022/0016143 A1 · Inhibitors of arg1 and/or arg2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016143 A1
- Document ID: US20220016143A1
- Status: Published application
- Kind: A1
- Application number: 17/294,353
- Filed: 2019-11-15
- Published: 2022-01-20
- Earliest claimed: 2018-11-16
- Assignees: Arcus Biosciences, Inc.
- Applicants: Arcus Biosciences, Inc.
- Inventors: Joel BEATTY; Eric Thomas NEWCOMB; Jay Patrick POWERS; Brandon Reid ROSEN; Yongli SU; Anh Thu TRAN; Corinne Nicole FOLEY; Rebecca Louise GRANGE; Tezcan GUNEY; Steven Donald JACOB; Jaroslaw KALISIAK; Manmohan Reddy LELETI; Erick Allen LINDSEY; Debashis MANDAL
- Web page: https://patentgrep.com/patent/US20220016143A1

## CPC

- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- A61K 31/282: Platinum compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- C07F 5/025: {Boronic and borinic acid compounds}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

## Claims

### Claim 1

A compound having the Formula (I)
or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein, X is N or CR4a;
each R1 is independently H or C1-8 alkyl;
R2 is H or CH3;
each R3 is independently H or C1-8 alkyl; or two R3 groups are joined together to form a 5 or 6-membered ring which is unsubstituted or substituted with from 1 to 4 Ra;
each R4a, R4b, R4c and R4d is independently selected from the group consisting of H, halogen, CN, C1-8 alkyl, C1-8 alkoxy, C1-8 hydroxyalkyl, C1-8 haloalkyl, C1-8 haloalkoxy, —X1—Y, —X1—SO2R5a and —X1—NR5bR5c;
each R5a, R5b and R5c is independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkylC(O)—, C3-7 cycloalkyl, 3- to 7-membered heterocycloalkyl, aryl, heteroaryl and an amino acid, or R5b and R5c are joined together to form a 4- to 6-membered ring; and wherein each of the 4- to 6-membered ring, C3-7 cycloalkyl or 3- to 7-membered heterocycloalkyl, aryl and heteroaryl, are unsubstituted or substituted with from 1 to 4 Rb;
each X1 is a bond, —O—, C1-6 alkylene or —O—C1-6 alkylene, wherein the alkylene portions are unsubstituted or substituted with 1 to 4 Rc and 0 or 1 oxo;
each Ra, Rb and Rc is independently halogen, CN, OH, NH2, CO2H, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl and phenyl, or two RC are combined to form a C3-6 cycloalkyl which is unsubstituted or substituted with 1 to 3 Rd;
each Y is independently phenyl, a 5- or 6-membered heteroaryl, 3- to 7-membered heterocycloalkyl, or C3-6 cycloalkyl, each of which is unsubstituted or substituted with from 1 to 3 Rd; and
each Rd is independently halogen, C1-4 alkyl, amino, aminoC1-4 alkyl, C1-4 haloalkyl, OH, and C1-4 hydroxyalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein:
X is N or CR4a;
each R1 is independently H or C1-8 alkyl;
R2 is H or CH3;
each R3 is independently H or C1-8 alkyl; or two R3 groups are joined together to form a 5 or 6-membered ring which is unsubstituted or substituted with from 1 to 4 Ra;
each R4a, R4b, R4c and R4d is independently selected from the group consisting of H, halogen, CN, C1-8 alkyl, C1-8 alkoxy, C1-8 hydroxyalkyl, C1-8 haloalkyl, —X1—Y, —X1—SO2R5a and —X1—NR5bR5c;
each R5a, R5b and R5c is independently selected from the group consisting of H, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkylC(O)—, C3-7 cycloalkyl, 3- to 7-membered heterocycloalkyl, aryl, heteroaryl and an amino acid, or R5b and R5c are joined together to form a 4- to 6-membered ring; and wherein each of the 4- to 6-membered ring, C3-7 cycloalkyl or 3- to 7-membered heterocycloalkyl, aryl and heteroaryl, are unsubstituted or substituted with from 1 to 4 Rb;
each X1 is a bond or C1-6 alkylene which is unsubstituted or substituted with 1 to 4 Rc;
each Ra, Rb and Rc is independently halogen, CN, OH, NH2, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl and phenyl, or two Rc are combined to form a C3-6 cycloalkyl;
each Y is independently phenyl or a 5- or 6-membered heteroaryl, each of which is unsubstituted or substituted with from 1 to 3 Rd; and
each Rd is independently halogen, C1-4 alkyl, amino, aminoC1-4 alkyl, C1-4 haloalkyl, OH, and C1-4 hydroxyalkyl.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, having the formula:

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, having the formula:

### Claim 5 (depends on 4)

The compound of claim 4, having the formula:

### Claim 6 (depends on 5)

The compound of claim 5, having the formula:

### Claim 7 (depends on 6)

The compound of claim 6, having the formula:

### Claim 8 (depends on 7)

The compound of claim 7, having the formula:

### Claim 9 (depends on 8)

The compound of claim 8, having the formula:

### Claim 10 (depends on 8)

The compound of claim 8, having the formula:

### Claim 11 (depends on 8)

The compound of claim 8, having the formula:

### Claim 12 (depends on 11)

The compound of claim 11, wherein R4b is selected from the group consisting of H, CH3, CN, CF3, F and Cl.

### Claim 13 (depends on 11)

The compound of claim 11, having the formula:

### Claim 14 (depends on 11)

The compound of claim 11, having the formula:

### Claim 15 (depends on 14)

The compound of claim 14, having a formula selected from the group consisting of:

### Claim 16 (depends on 1, 2)

The compound of claim 1 or 2, selected from those compounds of Table 1.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition, comprising a compound of any one of claims 1 to 16, and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treating a disease, disorder, or condition, mediated at least in part by ARG1, ARG2 or both ARG1 and ARG2, said method comprising administering a therapeutically effective amount of a compound of any one of claims 1 to 16 to a subject in need thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein said disease, disorder, or condition is mediated at least in part by ARG1.

### Claim 20 (depends on 18)

The method of claim 18, wherein said disease, disorder, or condition is mediated at least in part by ARG2.

### Claim 21 (depends on 18)

The method of claim 18, wherein said disease, disorder, or condition is mediated at least in part by ARG1 and ARG2.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein said compound is administered in an amount effective to reverse, stop or slow the progression of arginase-mediated immunosuppression.

### Claim 23 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein said disease, disorder, or condition is cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein said cancer is a cancer of the prostate, colon, rectum, pancreas, cervix, stomach, endometrium, brain, liver, bladder, ovary, testis, head, neck, skin (including melanoma and basal carcinoma), mesothelial lining, white blood cell (including lymphoma and leukemia), esophagus, breast, muscle, connective tissue, lung (including small-cell lung carcinoma and non-small-cell lung carcinoma), adrenal gland, thyroid, kidney, or bone; or is colorectal cancer, head and neck cancer, glioblastoma, mesothelioma, renal cell carcinoma, gastric carcinoma, sarcoma (including Kaposi's sarcoma), choriocarcinoma, cutaneous basocellular carcinoma, or testicular seminoma.

### Claim 25 (depends on 24)

The method of claim 24, wherein said cancer is selected from the group consisting of melanoma, colorectal cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, a brain tumor, lymphoma, ovarian cancer, Kaposi's sarcoma, renal cell carcinoma, head and neck cancer, and esophageal cancer.

### Claim 26 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein said disease, disorder, or condition is an immune-related disease, disorder or condition.

### Claim 27 (depends on 26)

The method of claim 26, wherein said immune-related disease, disorder, or condition is selected from the group consisting of rheumatoid arthritis, kidney failure, lupus, asthma, psoriasis, colitis, pancreatitis, allergies, fibrosis, anemia fibromyalgia, Alzheimer's disease, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, osteoporosis, Parkinson's disease, infections, Crohn's disease, ulcerative colitis, allergic contact dermatitis and other eczemas, systemic sclerosis and multiple sclerosis.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A combination comprising a compound of any one of claims 1 to 16, and at least one additional therapeutic agent.

### Claim 29 (depends on 28)

The combination of claim 28, wherein said at least one additional therapeutic agent is a chemotherapeutic agent, an immune- and/or inflammation-modulating agent, or radiation.

### Claim 30 (depends on 28)

The combination of claim 28, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject.

### Claim 31 (depends on 30)

The combination of claim 30, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject by inhibiting CD73.

### Claim 32 (depends on 30)

The combination of claim 30, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject by inhibiting A2aR and/or A2bR.

### Claim 33 (depends on 28)

The combination of claim 28, wherein said at least one additional therapeutic agent is an immune checkpoint inhibitor.

### Claim 34 (depends on 33)

The combination of claim 33, wherein said immune checkpoint inhibitor blocks the activity of at least one of PD1, PDL1, BTLA, LAG3, a B7 family member, TIM3, TIGIT or CTLA4.

### Claim 35 (depends on 34)

The combination of claim 34, wherein said immune checkpoint inhibitor blocks the activity of PD1 or PDL1.

### Claim 36 (depends on 35)

The combination of claim 35, wherein said immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, avelumab, atezolizumab, and durvalumab.

### Claim 37 (depends on 35, 36)

The combination of claim 35 or 36, further comprising an additional therapeutic agent that blocks the activity of TIGIT.

### Claim 38 (depends on 37)

The combination of claim 37, wherein said additional therapeutic agent blocks the activity of TIGIT by activating its ligand.

### Claim 39 (depends on 33)

The combination of claim 33, wherein said immune checkpoint inhibitor blocks the activity of TIGIT.

### Claim 40 (depends on 39)

The combination of claim 39, wherein said immune checkpoint inhibitor blocks the activity of TIGIT by activating its ligand.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The combination of any one of claims 33 to 40, further comprising a therapeutic agent that modulates the level of adenosine in a subject.

### Claim 42 (depends on 41)

The combination of claim 41, wherein said therapeutic agent modulates the level of adenosine in a subject by inhibiting CD73.

### Claim 43 (depends on 41)

The combination of claim 41, wherein said therapeutic agent modulates the level of adenosine in a subject by inhibiting inhibiting A2aR and/or A2bR.

### Claim 44 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The combination of any one of claims 30 to 43, further comprising a chemotherapeutic agent.

### Claim 45 (depends on 44)

The combination of claim 44, wherein said chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent.

### Claim 46 (depends on 45)

The combination of claim 45, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and doxorubicin.

### Claim 47 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The combination of any one of claims 30 to 46, further comprising radiation.

### Claim 48 (depends on 28)

The combination of claim 28, wherein said at least one additional therapeutic agent is a chemotherapeutic agent.

### Claim 49 (depends on 48)

The combination of claim 48, wherein said chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent.

### Claim 50 (depends on 49)

The combination of claim 49, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and doxorubicin.

### Claim 51 (depends on 48, 49, 50)

The combination of any one of claims 48 to 50, further comprising radiation.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treating cancer in a subject, said method comprising administering to said subject an effective amount of a compound of any one of claims 1 to 16 and at least one additional therapeutic agent.

### Claim 53 (depends on 52)

The method of claim 52, wherein said at least one additional therapeutic agent is a chemotherapeutic agent, an immune- and/or inflammation-modulating agent, or radiation.

### Claim 54 (depends on 52)

The method of claim 52, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject.

### Claim 55 (depends on 54)

The method of claim 54, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject by inhibiting CD73.

### Claim 56 (depends on 54)

The method of claim 54, wherein said at least one additional therapeutic agent modulates the level of adenosine in a subject by inhibiting A2aR and/or A2bR.

### Claim 57 (depends on 52)

The method of claim 52, wherein said at least one additional therapeutic agent is an immune checkpoint inhibitor.

### Claim 58 (depends on 57)

The method of claim 57, wherein said immune checkpoint inhibitor blocks the activity of at least one of PD1, PDL1, BTLA, LAG3, a B7 family member, TIM3, TIGIT or CTLA4.

### Claim 59 (depends on 58)

The method of claim 58, wherein said immune checkpoint inhibitor blocks the activity of PD1 or PDL1.

### Claim 60 (depends on 59)

The method of claim 59, wherein said immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, lambrolizumab, avelumab, atezolizumab, and durvalumab.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, further comprising an additional therapeutic agent that blocks the activity of TIGIT.

### Claim 62 (depends on 61)

The method of claim 61, wherein said additional therapeutic agent blocks the activity of TIGIT by activating its ligand.

### Claim 63 (depends on 57)

The method of claim 57, wherein said immune checkpoint inhibitor blocks the activity of TIGIT.

### Claim 64 (depends on 63)

The method of claim 63, wherein said immune checkpoint inhibitor blocks the activity of TIGIT by activating its ligand.

### Claim 65 (depends on 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 57 to 64, further comprising administering a therapeutic agent that modulates the level of adenosine in said subject.

### Claim 66 (depends on 65)

The method of claim 65, wherein said therapeutic agent modulates the level of adenosine in said subject by inhibiting CD73.

### Claim 67 (depends on 65)

The method of claim 65, wherein said therapeutic agent modulates the level of adenosine in said subject by inhibiting A2aR and/or A2bR.

### Claim 68 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 54 to 67, further comprising a chemotherapeutic agent.

### Claim 69 (depends on 68)

The method of claim 68, wherein said chemotherapeutic agent comprises a platinum-based or anthracycline-based chemotherapeutic agent.

### Claim 70 (depends on 69)

The method of claim 69, wherein said chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, and doxorubicin.

### Claim 71 (depends on 68, 69, 70)

The method of any one of claims 68 to 70, further comprising radiation.

### Claim 72 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 52 to 71, wherein said compound and said at least one additional therapeutic agent are administered in combination.

### Claim 73 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 52 to 71, wherein said compound and said at least one additional therapeutic agent are administered sequentially.

### Claim 74 (depends on 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 52 to 71, wherein said treatment periods for the administration of said compound and said at least one additional therapeutic agent overlap.
